Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus R-CHOP vs R-CHOP in newly diagnosed non-GCB/ABC DLBCL
CTR20140436Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Janssen Pharmaceutical. Started Jan 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20140436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140436.